等待开盘 03-26 09:30:00 美东时间
-0.090
-0.73%
Citizens analyst James McCanless initiates coverage on Smith Douglas Homes (NYSE:SDHC) with a Market Perform rating.
03-24 19:19
今日重点评级关注:Freedom Capital Markets:维持LifeMD"买入"评级,目标价从8美元升至10美元;Chardan Capital:维持Opus Genetics"买入"评级,目标价从9美元升至11美元
03-13 09:59
Wells Fargo analyst Sam Reid maintains Smith Douglas Homes (NYSE:SDHC) with a Equal-Weight and lowers the price target from $18 to $14.
03-12 21:07
Companies Reporting Before The Bell • Sprinklr (NYSE:CXM) is estimated to repor...
03-11 19:11
Smith Douglas Homes (NYSE:SDHC) reported quarterly earnings of $0.39 per share which beat the analyst consensus estimate of $0.12 by 230.51 percent. This is a 15.22 percent decrease over earnings of $0.46 per share from
03-11 19:05
今日重点评级关注:Canaccord Genuity:维持Fractyl Health"买入"评级,目标价从6美元升至8美元;HC Wainwright & Co.:维持MediWound"买入"评级,目标价从31美元升至36美元
2025-11-24 11:23
JP Morgan analyst Andrew Azzi assumes Smith Douglas Homes (NYSE:SDHC) with a Neutral rating and announces Price Target of $17.
2025-11-21 22:27
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
2025-11-10 17:17
<span style="color:#999999;">编者按:聚焦公司高管观点与展望,深挖业绩背后的信息,助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Smith Douglas Homes Corp. (SDHC) 2025年第三季度业绩会实录,以下是财务业绩回顾摘要: ## 1. 财务业绩 **营收表现:** 第三季度住宅销售收入为2.62亿美元,同比下降6%(去年同期为2.778亿美元)。房屋交付量为788套,同比下降3%(去年同期为812套)。平均销售价格为33.3万美元,同比下降2.6%。 **盈利能力:** 税前收入为1,720万美元,同比大幅下降56.5%(去年同期为3,960万美元),其中包含160万美元的土地期权交易放弃费用。净收入为1,620万美元,同比下降57.1%(去年同
2025-11-10 12:18
今日重点评级关注:HC Wainwright & Co.:维持Adicet Bio"买入"评级,目标价从4美元升至9美元;Citizens: 维持Rapport Therapeutics"跑赢大市"评级,目标价从77美元升至80美元
2025-11-10 10:22